Refine by
Molecular Disease Diagnostics Articles & Analysis
115 news found
Alfa Chemistry, a globally recognized chemical supplier, has recently announced its expanded range of services for customized synthesis of biotinylation reagents. Biotinylation, a widely used biological technique, involves the covalent attachment of biotin to biomolecules such as proteins, peptides, and nucleic acids. This technique plays a crucial role in various research fields, including ...
Medical Equipment Pump Solutions Industry Overview IVD, which stands for in vitro diagnostics, refers to products that conduct testing on samples taken from the human body (such as blood, body fluids, and tissues) outside of the body in order to obtain clinical diagnostic information. The IVD industry is subdivided into various sectors including immunodiagnostics, clinical chemistry, molecular ...
Creative BioMart, one of the world leading biotechnology companies serving science, recently updated its R-PEAPC Conjugated Proteins offerings to meet different research needs and applications. R-PE Labeled Proteins are labeled products generated by combining R-PE fluorescent dyes with proteins. R-PE labeled protein is non-toxic, odorless, and has high stability. And when the excitation ...
It provides customers with comprehensive solutions including instruments, consumables, reagents, and software for the analysis of gene loci related to birth defect prevention and control, drug genomes, tumours, infectious diseases, and other fields.GETOTEC, a fully-automated capillary electrophoresis instrument, ClinCap 1000, with independent intellectual property rights under ...
BIOMARK RECEIVES FUNDING SUPPORTING RESEARCH AND DEVELOPMENT PROJECT FOR CANCER TREATMENT MONITORING Vancouver, British Columbia – (February 7th, 2023) – BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF), an advanced stage liquid biopsy company with a focus on hard to detect and treat ...
Vancouver, British Columbia – (January 11, 2023) – BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce several updates from ongoing clinical trial using the Company’s liquid biopsy test for ...
The results demonstrated the high accuracy of BioMark’s quantitative metabolomic platform to identify early-stage lung cancer in retrospective plasma samples from individual with smoking history compared to participants suffering from other lung diseases including asthma, COPD, bronchiectasis and COVID. The poster is accessible on the Company website. ...
Vancouver, British Columbia – (October 27th, 2022) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce today the publication of a preclinical study demonstrating therapeutic capabilities of its SAT1 cancer marker in glioblastoma (GB) ...
DR CHENG BOON, ONCOLOGIST IN THE PRIVATE SECTOR AND THE NHS AS WELL AS ACTING AS ONCODNA UK MEDIAL DIRECTOR COMMENTED: “In my view, this is an important first step in a collaboration that will make it much easier for public and privately practising oncologists to access biopsy tissue and request ONCODEEP* for the purpose of routine next generation sequencing. This unique public-private ...
Anavasi Diagnostics ('Anavasi'), a medical technology company focused on the development of novel molecular diagnostic testing, recently announced the addition of a Chief Financial Officer, Chief Operating Officer and Chief Commercial Officer to its management roster. Scott Hales, Chief Financial Officer of Anavasi Diagnostics, has 30 years of financial, operational and strategic advisory ...
BillionToOne , Inc., a molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, announces the launch of their UNITY fetal antigen single-gene non-invasive prenatal test (sgNIPT), a new addition to UNITY Screen. ...
Comprising a team of scientist-founders, experienced biopharma veterans, and talented researchers, Mammoth is developing a robust pipeline of novel CRISPR systems capable of providing permanent cures for genetic conditions, and powering next-generation diagnostic tools to enable decentralized disease detection. “On behalf of the entire Mammoth team, we are ...
The technology can also be used as a surveillance tool for recurring disease. BioMark is currently pursuing two clinical trials using this liquid biopsy platform that can improve identification and assessing response to treatment for patients with lung cancer and glioblastoma. ...
The company is developing a novel rapid diagnostic test that will enable healthcare professionals to provide earlier and more targeted treatment of sepsis – a global healthcare problem that is more common than heart attack and claims more lives than any cancer. Infectious disease testing (including sepsis) is one of the fastest growing ...
The Company will be presenting clinical data using its quantitative metabolomic platform to identify early-stage lung cancer in retrospective plasma samples from individual with smoking history, or suffering from other lung diseases including asthma, COPD, bronchiectasis and COVID. The interim data analysis from 813 plasma samples will be presented during the ESMO Congress 2022 ...
Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG), a fully integrated commercial company that provides clinically relevant molecular diagnostic tests and pathology services for improved patient diagnosis and management, today announced new clinical validation data for their thyroid cancer test platform which is comprised of a mutation panel ...
Molecular Health, an international biotech IT company based in Heidelberg, Germany, has received European Union certification for its MH Guide clinical decision support software (SaaS) under the new In Vitro Diagnostics Regulation (EU) 2017/746 (IVDR). The MH Guide software, which is used in molecular pathology laboratories, is the first of its kind in Europe to receive this certification. The ...
HiberGene Diagnostics, the leading manufacturer of molecular diagnostics products in Ireland, is pleased to announce that it will supply its innovative point-of-care (POC) and near-patient testing solutions directly to healthcare providers in the UK and Ireland. These high-quality testing solutions cover infectious and transmissible ...
BillionToOne, Inc., a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, announces the launch of its first oncology liquid biopsy products, Northstar Select™ and Northstar Response™. ...
Anavasi Diagnostics ('Anavasi'), a medical technology company focused on the development of novel molecular diagnostic testing, has announced the addition of Scott Robitaille as Vice President of Sales & Marketing. Robitaille joins Anavasi with in-depth knowledge of the medical device and molecular diagnostics sector and over two decades of sales, marketing, and channel management ...